Advanced Oxygen Therapy Inc. (AOTI) is a privately owned USA company with an established Irish manufacturing subsidiary. AOTI has developed and commenced marketing its multi-modality Topical Wound Oxygen (TWO2®) therapy for use in both homecare and institutional settings. All of the company’s TWO2® products are FDA cleared, CE marked and Health Canada licensed.
With a disruptive globally patented technology and an extensive growing portfolio of level 1A RCT clinical evidence, demonstrating unparalleled healing efficacy and health economic benefits, AOTI is uniquely positioned to revolutionize the treatment of advanced wound types. Initial focus for the company is the underserved and growing chronic diabetic ulcer, venous ulcer and pressure ulcer market segments.
AOTI’s unique cyclical pressure TWO2® therapy is fast becoming the standard-of-care for patients with non-healing diabetic and venous ulcers and is predominantly delivered in the lower cost-of-care Homecare setting. Building on already obtained reimbursement in some key USA market segments and having delivered over 1,500,000 therapies to date, AOTI is well positioned to continue its rapid and profitable growth by soon achieving broad scale coverage throughout the USA and further penetrating the global wound care markets.